FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Dextran topics
Recombinant
Recombinant Protein
Ophthalmic
Ascorbic Acid
Polysaccharides
Ethylene Glycol
Hydroquinone
Cultured Cells
Culture Media
Epithelial
Epithelial Cell
Eukaryotic
Fibroblast
Cell Culture Media
Magnetic Field

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Dextran patents



      
           
This page is updated frequently with new Dextran-related patent applications. Subscribe to the Dextran RSS feed to automatically get the update: related Dextran RSS feeds. RSS updates for this page: Dextran RSS RSS


Date/App# patent app List of recent Dextran-related patents
03/26/15
20150086525
 Prebiotic composition or pharmaceutical composition synthesized from catalytic domains producing highly alpha-1,2 branched dextran patent thumbnailnew patent Prebiotic composition or pharmaceutical composition synthesized from catalytic domains producing highly alpha-1,2 branched dextran
The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with .alpha.(1.fwdarw.2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes and vectors containing the same..
Institut National Des Sciences Appliquees (insa)
03/19/15
20150079659
 Serum-free mammalian cell culture medium, and uses thereof patent thumbnailSerum-free mammalian cell culture medium, and uses thereof
The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate.
Life Technologies Corporation
03/05/15
20150064711
 Assay label patent thumbnailAssay label
This invention relates to an assay label comprising an amorphous carbon particle, a functionalised dextran polymer attached to the surface of the carbon particle and a first member of a complementary binding pair covalently bonded to the functionalised dextran polymer. The invention also provides a device incorporating the assay label, which further comprises a radiation source adapted to generate a series of pulses of electromagnetic radiation at a wavelength such that the absorption of the radiation by the label generates energy by non-radiative decay; a sample chamber containing a transducer having a pyroelectric or piezoelectric element and electrodes which is capable of transducing energy generated by non-radiative decay into an electrical signal; and a detector which is capable of detecting the electrical signal generated by the transducer..
Vivacta Limited
01/22/15
20150023876
 Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders patent thumbnailCompositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
A method of diagnosing a cd206 expressing cell-related disorder by administering a pharmaceutical composition to a subject, the composition including a carrier molecule having a detectable moiety attached thereto. The carrier molecule has a dextran backbone, and at least one receptor substrate conjugated, directly or indirectly, to the dextran backbone, wherein the receptor substrate is chosen so as to specifically bind to cd206.
Ohio State Innovation Foundation
01/01/15
20150004140
 Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans patent thumbnailCompositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kda and 70 kda, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity.
Tate & Lyle Ingredients France Sas
11/20/14
20140343013
 Stabalized glycosaminoglycan preparations and related methods patent thumbnailStabalized glycosaminoglycan preparations and related methods
Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain nitrogen containing polymers (e.g., polylysine, polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).
11/20/14
20140341874
 Dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair patent thumbnailDextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair
The invention relates to a dextran-based tissuelette comprising platelet-rich plasma lysate (prpl), which can be used for tissue repair. In particular, the tissuelette of the present invention can be adapted to display properties similar to natural cartilage, while having increased chondrocyte-attraction.
11/06/14
20140328768
 Iron oxide nanocapsule,  manufacturing the same, and mri contrast agent using the same patent thumbnailIron oxide nanocapsule, manufacturing the same, and mri contrast agent using the same
Provided is an iron oxide nanocapsule which has extremely excellent water dispersibility, which is very stable in the body and which has very excellent mri contrast ability, a method of manufacturing the same, and an mri contrast agent using the same. The method of manufacturing the iron oxide nanocapsule includes the steps of: thermally decomposing an iron complex to prepare hydrophobic ligand-bonded iron oxide nanoparticles; and encapsulating the hydrophobic ligand-bonded iron oxide nanoparticles by a carboxymethyldextrandodecylamine conjugate encapsulation material or a dextran-linoleic acid conjugate encapsulation material to form an iron oxide nanocapsule..
10/23/14
20140316302
 Sample collection kit patent thumbnailSample collection kit
A sample collection kit includes a sample collector, a polycarbonate container, and a preservative solution. The sample collector includes an absorbent pad with a collecting element that receives a sample of oral fluid.
10/23/14
20140315855
 Antidandruff agent sulfated polysaccharides patent thumbnailAntidandruff agent sulfated polysaccharides
The invention relates to the cosmetic use of a sulfated polysaccharide chosen from: dextran sulfate and sulfated polysaccharides derived from the red alga porphyridium sp, as active agent for preventing and/or treating dandruff of the scalp.. .
10/16/14
20140308368

Ophthalmological aqueous composition


The present invention provides an aqueous ophthalmic composition containing (a) a terpenoid, (b) zinc chloride, and (c) at least one member selected from the group consisting of cellulose-based polymeric compounds, vinyl-based polymeric compounds, polyethylene glycols and dextran. According to the present invention, an aqueous ophthalmic composition is provided in which adsorption of the terpenoid to a container can be inhibited, thereby making it possible to inhibit the reduction in the terpenoid content for a long period of time, the aqueous ophthalmic composition having some excellent actions such as an inhibitory action for histamine release, and an inhibitory action for discharges from the eyes..
10/02/14
20140296509

Polyol and polyether iron oxide complexes as pharmacological and/or mri contrast agents


Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran.
09/25/14
20140287061

In-situ cross-linkable polymeric compositions and methods thereof


A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or deae-dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride.
09/11/14
20140256831

Hydrogel and producing same


A hydrogel is provided which is obtained by reacting an azide group and a cyclooctyne group in the absence of a catalyst, especially in the absence of a copper catalyst. The hydrogel has: (a) a first polymer moiety composed of hyaluronic acid, carboxymethyl dextran or the like; (b) a second polymer moiety composed of hyaluronic acid, carboxymethyl dextran or the like, said second polymer moiety being of a kind that is same as or different from the kind of the moiety (a) and is composed of a molecule different from the moiety (a); and (c) a triazole ring group or a derivative group thereof..
09/11/14
20140255905

Medical fluid comprising globulin and its use for preservation of harvested organs


A medical fluid for a harvested organ, tissue or parts thereof, for evaluation and/or preservation. The fluid comprise oncotic agents, comprising albumin, a dextran compound and at least one globulin.
08/21/14
20140234226

Plasmonic stable fluorescence superparamagnetic iron oxide nanoparticles and a synthesizing the same


The various embodiments herein provide for the engineered multimodal super paramagnetic iron oxide nanoparticles (spions) with a fluorescent dye. The spions comprise fluorescent polymer dye arranged in a gap between a spion core and a gold shell.
07/31/14
20140213499

Benefit agent delivery particles comprising dextran


The invention provides a composition comprising a benefit agent delivery particle comprising dextran as a delivery aid. The benefit agent delivery particle may further comprise a non-polysaccharide polymer, preferably an aminoplast polymer.
07/24/14
20140206644

Methods and compositions for inhibiting cellular proliferation and surgical adhesion


The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery.
06/26/14
20140178310

Polyol and polyether iron oxide complexes as pharmacological and/or mri contrast agents


Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran.
06/19/14
20140168331

Inkjet inks


The present disclosure provides inkjet inks and associated methods and systems. In one example, an inkjet ink can comprise an ink vehicle and a colorant, wherein the ink vehicle includes an organic co-solvent, water, and from 0.0001 wt % to 0.1 wt % dextran based on the inkjet ink as a whole..
06/12/14
20140161895

Pharmaceutical compositions of dextran polymer derivatives


Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative.
06/05/14
20140154678

Clearance buffer


The invention concerns a composition comprising tcep, biotin and dextran suitable for liquefying a viscous biological sample. The composition according to the invention can be used in diagnostic methods, preferably for use in diagnosis of an infection with a micro-organism, more preferably for use in diagnosis of hcap..
05/22/14
20140142294

Method for manufacture of dextran, dextran solution obtained, and uses


Microbiological method of production of a dextran solution, according to which a culture medium containing sucrose is inoculated with a preculture of a bacterial strain that is able to produce dextran, then the dextran solution obtained at the end of fermentation is recovered directly, without a subsequent concentration step, characterized in that:—before inoculation, the culture medium contains at least 10 wt. % of sucrose,—after inoculation, sucrose is added again in conditions such that the total amount of sucrose in the medium, including that present before inoculation, is at least 16 wt.
05/15/14
20140135286

Compositions and methods for inhibiting adhesion formation


Compositions and methods are provided for preparing an adhesion barrier that effectively reduce, prevent or treat adhesions in a patient in need thereof. In one embodiment, a matrix is provided comprising a biodegradable polymer and dextran loaded in the matrix in an amount of from about 5% to about 90% by weight based on a total weight of the matrix.
05/15/14
20140135285

Devices and methods for inhibiting adhesion formation


Methods and compositions are provided for reducing, treating or preventing adhesions in a patient in need of such treatment. In one embodiment, an implantable device is provided for reducing or preventing adhesion formation at a post-operative tissue site in a patient, the implantable device including a biodegradable porous matrix comprising dextran, wherein the implantable device is capable of releasing the dextran over at least 2 days..
05/15/14
20140135273

Cb-183,314 compositions and related methods


The present disclosure provides novel solid cb-183,315 formulations which have improved chemical stability. The chemical stability of the solid cb-183,315 is dependent on the process by which the composition is made.
05/15/14
20140134226

Compositions and methods for inhibiting bone growth


Compositions and methods are provided for a matrix that inhibits bone growth in a patient in need thereof. In one embodiment, a method of inhibiting bone growth is provided, the method comprising: implanting a matrix at a target tissue site, the matrix comprising a biodegradable polymer and dextran loaded in the matrix in an amount of from about 5% to about 95% by weight based on a total weight of the matrix..
05/01/14
20140121512

In vivo visualization of lymphatic tissue


Aspects of the invention include methods for visualizing lymphatic tissue in an ocular region, e.g., the cornea, of a living subject, such as a mouse or human. In certain embodiments, the methods include contacting the region with a fluorescently-labeled lymphatic tissue-specific dye, e.g., fitc or rhodamine labeled dextran, and detecting the labeled dye to visualize lymphatic tissue in the region, where the visualization may vary, from an image obtained at a single time to a video over a period of time.
04/10/14
20140100111

Seed coating hydrogels


A bio-degradeable seed coating composition for enhanced seed protection and propagation comprises a gelatin-based hydrogel formulation consisting of a naturally derived, hydrophilic protein in combination with a sulfated or non-sulfated polysaccharide. The protein is animal porcine or bovine derived while the polysaccharide is preferably a cellulose derivative such as sodium cellulose sulfate, dextran sulfate, sulfated chitosan, sulfated starch and mixtures thereof.
04/03/14
20140094435

Use of dextran sulfate


A method of inhibiting instant blood-mediated inflammatory reaction (ibmir) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient.
04/03/14
20140093484

Use of dextran sulfate


A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.. .
02/27/14
20140058527

Cartilage repair mixture containing allograft chondrocytes


The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered pbs, dextran or mixed polymers with allograft chondrocytes added in an amount ranging from 2.5×105 to 2.5×107.. .
02/27/14
20140056818

Process for delivering encapsulated neutral bioimaging molecules, complex, and process thereof


The present disclosure relates to delivering neutral bioimaging molecules encapsulated within icosahedral dna capsules in vivo and in vitro. The present disclosure also discloses the entrapment of neutral bioimaging molecules like fitc dextran within the cavity of a dna polyhedron without any molecular recognition or chemical conjugation between host (dna icosahedron) and cargo (like fitc dextran).
02/20/14
20140050747

Trace elements


The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation preparation. The synchronisation preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation.
02/13/14
20140045788

Method of stably treating incontinence using a bulking agent


The invention provides a method for treating fecal incontinence in a subject comprising administering in an appropriate subject a therapeutically effective amount of a biocompatible bulking agent to the wall of the anal canal. The biocompatible bulking agent comprises dextranomer and a pseudoplastic carrier, such as, hyaluronic acid, and is stable and effective in treating fecal incontinence for over 24 months, and up to at least 36 months or more following an initial administration..
02/13/14
20140045787

Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion


An ophthalmic solution is provided. The ophthalmic solution is hypertonic.
02/13/14
20140045786

Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion


An ophthalmic solution is provided. The ophthalmic solution is hypertonic.
01/30/14
20140030303

Stabilized enzyme compositions


A medical device includes a base material having an immobilized enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kda).
01/23/14
20140023586

Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran


The subject invention relates to the compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran with technetium-99m and for stabilizing the dtpa-dextran cold kit. The composition contains stannous chloride ions to reduce 99mtc-pertechnetate, ascorbic acid to reduce stannic ions to stannous ions to maintain a reducing environment, α,α-trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and glycine to transchelate technetium-99m under highly acidic conditions to facilitate radiolabeling dtpa-dextran with high radiochemical purity.
01/09/14
20140010742

Method of increasing the stability of a bayer process liquor


Methods, and related products and compositions, of increasing the stability of a bayer process liquor are described. A method of increasing the stability of a bayer process liquor includes contacting the bayer process liquor with a ppm quantity of a low molecular weight dextran.
01/02/14
20140005379

Nanoparticle delivery system and components thereof


The present disclosure relates generally to a nanoparticle delivery system. The nanoparticles are formed from amphiphilic block copolymers comprising polylactide and dextran.
01/02/14
20140005142

Method of stably treating incontinence using a bulking agent


The invention provides a method for treating fecal incontinence in a subject comprising administering in an appropriate subject a therapeutically effective amount of a biocompatible bulking agent to the wall of the anal canal. The biocompatible bulking agent comprises dextranomer and a pseudoplastic carrier, such as, hyaluronic acid, and is stable and effective in treating fecal incontinence for over 24 months, and up to at least 36 months or more following an initial administration..
12/26/13
20130344518

Method for measuring cholesterol in hdl subfraction, and reagents and kit therefor


The present invention provides a method for simply and precisely measuring cholesterol in an hdl subfraction contained in a sample. This is a method for measuring cholesterol in hdl3 contained in a sample, which comprises reacting a sample with (1) a combination of a cholesterol ester hydrolase and a cholesterol oxidase or (2) a combination of a cholesterol ester hydrolase, an oxidized coenzyme and a cholesterol dehydrogenase in an aqueous medium containing: (a) a divalent metal salt; (b) an alkali metal salt selected from the group consisting of a sulfate, a nitrate, a carbonate, an acetate and a halide; and (c) dextran sulfate or a salt thereof, and measuring a substance formed or consumed in the reaction without separating and removing lipoproteins other than hdl3..
12/05/13
20130323182

Method of preparing iron oxide nanoparticles coated with hydrophilic material, and magnetic resonance imaging contrast agent using the same


The present invention relates to a method of preparing biocompatible iron oxide nanoparticles by coating iron oxide nanoparticles having improved magnetism via annealing treatment using salt particles with a hydrophilic material and to a magnetic resonance imaging (mri) contrast agent including the iron oxide nanoparticles prepared thereby. Among hydrophilic materials, carboxymethyl dextran (cm-dextran) is the most efficient in terms of stabilizing the annealed iron oxide nanoparticles and exhibiting contrast effects..
11/28/13
20130316977

Priming solutions for cardiopulmonary bypass


The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combination of oncotic and non-oncotic dextran molecules.
11/28/13
20130315839

Iron oxide nanoparticles as mri contrast agents and their preparing method


Iron oxide nano contrast agents for magnetic resonance imaging which have superior t2 contrast effect, and also can be used as a storage or a carrier for drugs and so on, are disclosed. The iron oxide nano contrast agents can be prepared by the steps of: coating surfaces of hydrophobic feo nanoparticles with a coating material selected from the group consisting of polyethylene glycol-phospholipid conjugate, dextran, chitosan, dimercaptosuccinic acid and mixtures thereof in an organic solvent to form hydrophilic feo nanoparticles having hydrophilic surfaces and dispersibility in water; dispersing the hydrophilic feo nanoparticles in water to oxidize feo; and exposing the oxidized hydrophilic feo nanoparticles to an acidic buffer to dissolve and remove interior unoxidized feo portions, and thereby to form fe3o4 nanoparticles having an interior space..
11/14/13
20130303983

Coated medical devices including a water-insoluble therapeutic agent


A medical device includes an implantable structure and a coating layer including a water-insoluble therapeutic agent and one or more additives selected from heparin, heparan sulfate, dextran and dextran sulfate, and physiologically-acceptable salts thereof. The one or more additives can be present in an amount effective to increase the rate of release of the water-insoluble therapeutic agent from the coating layer.
11/07/13
20130296285

Design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations


A prodrug according to formula (i) wherein r2 is a residue of a drug, said drug having a hydroxyl group by which the coor2 group is formed; z is o or nh; m is 0 or 1; and r3 is an organic moiety comprising a lipophilic group or a residue of a polymer, provided that z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles.
11/07/13
20130295667

Serum-free mammalian cell culture medium, and uses thereof


The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate.
10/24/13
20130280321

Method of inducing hemostasis in a wound


A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided.
09/26/13
20130253555

Ophthalmic surgical method comprising a step of at least partly removing the vitreous humour


An ophthalmic surgical method comprising a step of at least partly removing the vitreous humour, which also comprises a step of highlighting the vitreous to be removed using a coloured composition which selectively highlights the vitreous, allowing a distinction between the vitreous and the other structures of the eye, said distinction facilitating vitreous removal, wherein the coloured composition comprises a polymeric dye comprising at least one backbone to which at least one reactive dye is chemically linked; in a preferred embodiment the polymeric dye being a blue dextran.. .
09/19/13
20130245549

Bioresorable drug delivery matrices based on cross-linked polysaccharides, dosage forms designed for delayed/controlled release


Bioactive agents are embedded in a cross-linked dextran and coated with a bioresorbable polymer. When implanted in a mammal, the coated cross-linked dextran composition produces controlled release of the embedded bioactive agent..
09/19/13
20130244978

Ophthalmic composition


The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses or an ophthalmic composition/solution for contact lenses, which comprises (a) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (b) a terpenoid..
09/19/13
20130244974

Surgical hydrogel


A composition suitable for use in wound healing, particularly for reducing post-surgical adhesions, containing cross-linked derivatives of chitosan and dextran polymers. A hydrogel forms when solutions of the polymers are combined..
08/22/13
20130217867

Recombinant production of heparin binding proteins


A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.. .
08/01/13
20130195739

Cross-linked ethylsulfonated dihydroxypropyl cellulose


The invention provides methods and compositions for improving the production of alumina hydrate. The invention involves adding one or more cross-linked ethylsulfonated polysaccharides to liquor or slurry in the fluid circuit of the production process.
06/27/13
20130165771

Use of fitc-dextran as dye for fundus angiography and methods thereof


A novel fundus angiographic application and method using fluorescein isothiocyanate dextrans (fitc-dextran) as fluorescence angiographic dye for diagnosis and evaluation of eye diseases on humans is disclosed. The method involves the process of constitution of fitc-dextran solution and intravenous injection of the said solution, followed by observation and photography of ocular fundus circulation using a fluorescence fundus camera with an image system.
06/20/13
20130157974

Preparation comprising iron(iii) complex compounds and redox-active substance(s)


A preparation is disclosed that comprises one or more iron(iii) complex compounds which have a redox potential at ph 7 of from −324 mv to −750 mv relative to a normal hydrogen electrode (nhe), and one or more redox-active substances, wherein the carbohydrates are selected from the group consisting of dextrans and hydrogenated dextrans, dextrins, oxidised or hydrogenated dextrins, as well as pullulan, oligomers thereof and/or hydrogenated pullulans, and wherein the redox-active substance(s) is/are selected from the group consisting of ascorbic acid; vitamin e; cysteine; physiologically acceptable phenols/polyphenols selected from the group consisting of quercetin, rutin, flavones, flavonoids, hydroquinones; and glutathione, and in particular is ascorbic acid.. .
05/23/13
20130130969

Antimicrobial peptide, branched forms thereof and their use in the treatment of bacteria infections


The instant invention refers to an antibacterial peptide with all aminoacids in d-configuration, possessing strong antimicrobial activity against gram-negative and gram-positive bacteria and candida strains. The peptide can be in linear form or multimerised on a skeleton of polyacrylamide, of dextrane units or on a skeleton of ethylene glycol units.
05/16/13
20130121929

Polyol and polyether iron oxide complexes as pharmacological and/or mri contrast agents


Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran.
05/09/13
20130115200

Cell therapy


dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection. The dextran sulfate can therefore be used in a composition together with tumor infiltrating t-lymphocytes to treat metastatic cancer in a subject..
05/02/13
20130109633

Cb-183,315 compositions and related methods


The present disclosure provides novel solid cb-183,315 formulations which have improved chemical stability. The chemical stability of the solid cb-183,315 is dependent on the process by which the composition is made.
04/25/13
20130102977

Ophthalmic composition


The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (a) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (b) a terpenoid..
04/25/13
20130102730

Polyamine-containing polymers and methods of synthesis and use


The present invention relates to polyamine-containing polymers and methods of their synthesis and use. The polymer may be hydroxyethylcellulose, dextran, poly(vinyl alcohol) or poly(methyl acrylate)..
04/25/13
20130102561

Stabalized glycosaminoglycan preparations and related methods


Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain nitrogen containing polymers (e.g., polylysine, polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).
04/25/13
20130102079

Polyamine-containing polymers and methods of synthesis and use


The present invention relates to polyamine-containing polymers and methods of their synthesis and use. The polymer may be hydroxyethylcellulose, dextran, poly(vinyl alcohol) or poly(methyl acrylate)..


Popular terms: [SEARCH]

Dextran topics: Recombinant, Recombinant Protein, Ophthalmic, Ascorbic Acid, Polysaccharides, Ethylene Glycol, Hydroquinone, Cultured Cells, Culture Media, Epithelial, Epithelial Cell, Eukaryotic, Fibroblast, Cell Culture Media, Magnetic Field

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Dextran for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dextran with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         















0.4829

3102

1 - 1 - 72